STADA Group, a German generic drug manufacturer, has agreed to acquire the prescription and consumer health business of Ukrainian pharmaceutical producer Biopharma for an undisclosed price.
Swiss pharmaceutical company Novartis has opened a new manufacturing facility for cell and gene therapies at Stein in Switzerland.
Japan-based Asahi Kasei Group has signed an agreement to acquire Danish pharma company Veloxis Pharmaceuticals for DKK8.9bn ($1.3bn) in an all-cash deal.
Lupin has signed a definitive agreement to sell the entire stake in its Japanese subsidiary Kyowa Pharmaceutical to Unison, a Japanese private equity fund, for JPY57.36bn ($526m).
Novartis division Sandoz has signed a binding agreement to acquire Aspen Global’s Japanese business in a deal valued at around €400m ($441m).
Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia.
Japan-based Takeda Pharmaceutical has opened a new dengue vaccine manufacturing facility in Singen, Germany.
Samsung Biologics announced the signing of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis.
AstraZeneca has signed an agreement to sell Seroquel medicine rights in Europe and Russia to Cheplapharm Arzneimittel for around $239m.
Knight Therapeutics plans to acquire Brazilian pharma company Biotoscana Investments (GBT) for a price of around BRL1.16bn ($281m), which includes the latter’s financial debt.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.